Market Cap | 73.31M | P/E | - | EPS this Y | 82.80% | Ern Qtrly Grth | - |
Income | -21.81M | Forward P/E | -0.16 | EPS next Y | 28.00% | 50D Avg Chg | -32.00% |
Sales | 61k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
Dividend | N/A | Price/Book | 0.92 | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | 2.00 | Quick Ratio | 3.56 | Shares Outstanding | 2.59M | 52W Low Chg | 18.00% |
Insider Own | 10.42% | ROA | -81.53% | Shares Float | 1.37M | Beta | 1.02 |
Inst Own | 45.05% | ROE | -178.30% | Shares Shorted/Prior | 12.22K/5.13K | Price | 2.62 |
Gross Margin | 272.13% | Profit Margin | - | Avg. Volume | 313,865 | Target Price | 16.00 |
Oper. Margin | -35,560.66% | Earnings Date | May 13 | Volume | 65,333 | Change | -9.97% |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
JMP Securities | Market Outperform | Apr 22, 24 |
JMP Securities | Market Outperform | Feb 15, 24 |
JMP Securities | Market Outperform | Jan 24, 24 |
JMP Securities | Market Outperform | Sep 26, 23 |